Pierre Fabre Medicament

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

2 drugs in development

No phase data available.

By Therapeutic Area

top 1

Oncology

2100%

R&D Momentum

40/100

Pipeline Velocity

0/100

Trial Completion Rate

86/100

Pipeline Concentration

100/100

Pipeline Freshness

60/100

Activity

Recent Activity

Last 14 days

Jul 3, 2026

Active, not recruiting

Advanced Breast Cancer Patients Treated With Oral Vinorelbine: a Prospective and Retrospective, Observational Study - VINOREAL

Earlier

Oct 22, 2024TrialFIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Sep 17, 2024TrialStudy of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Sep 26, 2023TrialFirst-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Sep 22, 2023FDAExxua — EXXUA

Jun 27, 2023TrialStudy on Structum® in Adult Patients With Osteoarthritis (TRUST)

Sep 30, 2022TrialTreatment Patterns of Neratinib in HER2+ EBC in China

Aug 31, 2022TrialBioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

4 more events

Jun 22, 2022TrialA 6-months Observational Study to Evaluate the Quality of Life of Patients Treated With Phytotherapy or Alpha-blockers for Benign Prostatic Hyperplasia

Jun 2, 2022TrialPhase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

May 2, 2022TrialAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Sep 27, 2021TrialPhase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

1 patent group across drugs · Source: FDA Orange Book

DrugExpires

ExxuaSep 2, 2030

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Oncology

Nasopharyngeal Carcinoma

Tabelecleucel

Non-Small Cell Lung Cancer

STX-721/PFL-721 (RP2D)

Oncology

Nasopharyngeal Carcinoma

TabelecleucelPhase 2

Non-Small Cell Lung Cancer

STX-721/PFL-721 (RP2D)Phase 2

Regulatory

Regulatory Timeline

19941 event

FDADec 23

Navelbine — NAVELBINE

Application NDA020388 (NDA)

20231 event

FDASep 22

Exxua — EXXUA

Application NDA021164 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)